

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

in re Application of: Hill, et al.

For: CLOSED LOOP NEUROMODULATION FOR PREVENTION AND TREATMENT OF CARDIAC CONDITIONS

Serial No.: 10/035,319

Filed: October 26, 2001

RECEIVED

APR 12 2002

CERTIFICATE OF MAILING UNDER 37 CFR 1.8: I hereby certify that this INFORMATION DISCLOSURE

STATEMENT and the paper(s), as described herein, are being deposited in the U.S. Postal Service, as first class mail, addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231, on this 4th day of February, 2002.

Signature

Molly Chlebeck

Printed Name

Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

- ☒ Information Disclosure Statement
- ☒ PTO FORM 1449
- ☒ Copies cited references
- ☒ Return Postcard

FEE CALCULATION

- ☒ \$ 00.00 Pursuant to 37 CFR §1.97(b) (before mailing of first Office Action)
- ☐ \$ 00.00 Pursuant to 37 CFR §1.97(c) with Certification (cited in foreign application not more than 3 months earlier)
- ☐ \$ 00.00 Pursuant to 37 CFR §1.97(e) with Certification
- ☐ \$180.00 Pursuant to 37 CFR §1.97(c) without Certification
- ☐ \$180.00 Pursuant to 37 CFR §1.97(d) with Certification

- ☐ Applicant hereby petitions for a _____ months' extension of time. If an additional extension of time is required, please consider this petition therefor.
- ☒ Applicant believes that no extension of time is required. However, if an extension of time is required, please consider this a petition therefor to provide for the possibility that applicant has inadvertently overlooked the need for an extension of time.
- ☒ Please charge any additional fees or credits to Deposit Account No. 13-2546 which may have been overlooked with regard to this filing. A duplicate of this transmittal is enclosed.

Date

2/1/02

Beth L. McMahon

Reg. No. 41,987

#27581

Telephone: (763) 514-3066



PATENT
Docket: P-10124.00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Hill et al.

) Art Unit:

Serial No.: 10/035,319

) Examiner:

Filed: October 26, 2001

)

RECEIVED
APR 12 2002
TECHNOLOGY CENTER R3700

For: CLOSED LOOP NEUROMODULATION FOR PREVENTION AND TREATMENT
OF CARDIAC CONDITIONS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington D.C. 20231

Dear Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application.

Consideration of each of the documents listed on the attached Form 1449 is respectfully requested. Pursuant to the provisions of M.P.E.P. §609, Applicant further requests that a copy of the Form 1449, marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

Respectfully submitted,

Date: _____

2/12

By: _____


Beth L. McMahon

Beth L. McMahon

Reg. No. 41,987

#27581

Telephone: (763) 514-3066



FORM PTO-1449

(Rev. 2-32)

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.:
P-10124

SERIAL NO:

10/035319

RECEIVED
APR 12 2002

APPLICANT: Hill et al.

TECHNOLOGY CENTER R3700

FILING DATE:
October 26, 2001

GROUP:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE ISSUED	INVENTOR NAME	U.S. CLASS	U.S. SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	3522811	02/13/69	Seymour et al.	128	419	
	AB	3645267	02/29/72	Hagfors	128	421	
	AC	3650277	03/21/72	Sjostrand et al.	128	419C	
	AD	3796221	03/12/74	Hagfors	128	421	
	AE	4044774	08/30/77	Corbin et al.	128	404	
	AF	4146029	03/27/79	Ellinwood, Jr.	128	260	
	AG	4428378	01/31/84	Anderson et al.	128	419	
	AH	4549556	10/29/85	Tarjan et al.	128	785	
	AI	4903701	02/27/90	Moore et al.	128	419	
	AJ	5058584	10/22/91	Bourgeois	128	421	
	AK	5135004	08/04/92	Adams et al.	128	696	
	AL	5199428	04/06/93	Obel et al.	128	419	
	AM	5220917	06/22/93	Cammilli et al.	128	419	
	AN	5255691	10/26/93	Otten	607	117	
	AO	5330505	07/19/94	Cohen	607	6	
	AP	5342409	08/30/94	Mullett	607	46	
	AQ	5031618	07/16/91	Mullett	128	421	
	AR	5330507	07/19/94	Schwartz	607	14	
	AS	5330515	07/19/94	Rutecki et al.	607	46	
	AT	5331966	07/26/94	Bennett et al.	128	696	

EXAMINER

DATE CONSIDERED

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

(Rev. 2-32)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE STATEMENT
BY APPLICANT
(Use several sheets if necessary)ATTY. DOCKET NO.:
P-10124

SERIAL NO:

10/035319

RECEIVED

APR 12 2002

TECHNOLOGY CENTER PCTUJ

APPLICANT: Hill et al.

FILING DATE:
October 26, 2001

GROUP:

	AU	5360441	11/01/94	Otten	607	122	
	AV	5464434	11/07/95	Alt	607	6	
	AW	5564434	10/15/96	Halperin et al.	128	48	
	AX	5607418	03/04/97	Arzbaeher	604	891	
	AY	5817131	10/06/98	Elsberry et al.	607	5	
	AZ	5824021	10/20/98	Rise	607	46	
	BA	6058331	05/02/00	King	607	62	
	BB	6134470	10/17/00	Hartlaub	607	14	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE PUBLIC- ATION	COUNTRY	INT. CLASS	INT. SUB- CLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)

	BC	Braunwald, M.D. et al, Carotid Sinus Nerve Stimulation in the Treatment of Angina Pectoris and Supraventricular Tachycardia
	BD	Bilgutay, M.D. et al, Vagal Tuning – A New Concept in the Treatment of Supraventricular Arrhythmias, Angina Pectoris, and Heart Failure, Journal of Thorac Cardiovascular Surgery 56 (1): 71-82, July 1968
	BE	Foreman et al, Modulation of Intrinsic Cardiac Neurons by Spinal Cord Stimulation: Implications for its Therapeutic Use in Angina Pectoris, Cardiovascular Research 47, pp 367-375, April 10, 2000

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.